Basics CorMedix Inc. Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. IPO Date: May 13, 2010 Sector: Healthcare Industry: Biotech Market Cap: $949.19M Activated in VL: True Average Daily Range Avg Daily Range: $0.14 | 4.10% Avg Daily Range (30 D): $0.30 | 2.59% Avg Daily Range (90 D): $0.31 | 2.52% Institutional Daily Volume Avg Daily Volume: .58M Avg Daily Volume (30 D): 2.41M Avg Daily Volume (90 D): 2.82M Trade Size Avg Trade Size (Sh.): 208 Avg Trade Size (Sh.) (30 D): 117 Avg Trade Size (Sh.) (90 D): 123 Institutional Trades Total Inst.Trades: 694 Avg Inst. Trade: $1.5M Avg Inst. Trade (30 D): $1.64M Avg Inst. Trade (90 D): $1.58M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $1.84M Avg Closing Trade (30 D): $2.23M Avg Closing Trade (90 D): $2.36M Avg Closing Volume: 187.97K     News Sep 29, 2025 @ 12:30 PM CorMedix Announces Completion of Enrollment in Pha... Source: Globe Newswire Sep 2, 2025 @ 11:30 AM CorMedix Completes Acquisition of Melinta Therapeu... Source: Globe Newswire Dec 10, 2024 @ 7:45 AM Closed System Transfer Device Market Size Poised t... Source: Polaris Market Research Sep 9, 2024 @ 8:06 PM Here's Why CorMedix Is a Great 'Buy the Bottom' St... Source: Zacks Sep 9, 2024 @ 2:52 PM CorMedix Inc. Announces New Commercial Agreement Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $.8 $.29 $.32 Diluted EPS $.77 $.28 $.3 Revenue $ 121.48M $ 39.74M $ 39.08M Gross Profit $ 116.16M $ 37.87M $ 37.48M Net Income / Loss $ 51.16M $ 19.83M $ 20.64M Operating Income / Loss $ 49.32M $ 19.54M $ 20.13M Cost of Revenue $ 5.32M $ 1.86M $ 1.6M Net Cash Flow $ 130.77M $ 93.02M $ 25.63M PE Ratio 14.66     Splits Mar 26, 2019:   1:5